Table 4.
Estimated dihydroartemisinin and total anti-malarial activity pharmacokinetic parameters.
| Parameter | Estimate (SE) | Inter-subject variation CV% |
|---|---|---|
| DHA | ||
| Ka (h -1) | 4.271 (2.091) | |
| CL/F1 (L kg-1 h-1) | 0.636 (0.075) | |
| Increase in CL/F due to the 3rd dose period | 0.760 (0.160) | |
| V/F (L kg-1) | 2.285 (0.317) | 47% |
| Effect of Age on V/F | 0.063 (0.015) | |
| T 1/2 (h) | ||
| 1st dose | 2.5 [0.8–4.5]2 | |
| 3rd dose | 1.1 [0.4–2.0]2 | |
| σ (ng/mL) | 340 | |
| Anti-malarial Activity | ||
| Ka (h-1) | 4.744 (2.587) | |
| CL/F1 (L kg-1 h-1) | 0.616 (0.071) | |
| Increase in CL/F due to the 3rd dose period | 0.662 (0.150) | |
| V/F (L kg-1) | 2.134 (0.287) | 48% |
| Effect of Age on V/F | 0.063 (0.013) | |
| T 1/2 (h) | ||
| 1st dose | 2.4 [0.5–5.7]2 | |
| 3rd dose | 1.2 [0.2–2.7]2 | |
| σ (ng/mL) | 353 |
1population mean estimate of CL/F for the first dose period
290% range of predicted values;
Ka – absorption rate constant; CL/F – total clearance; V/F – volume of distribution; F – fraction of drug absorbed; σ – residual additive error in DHA units